Current Headlines
-
Automated High-Throughput Sorting Of Living Cells Using Laser Light And AI
3/12/2024
Tests on living cell cultures are becoming increasingly important for personalized medicine, drug development and clinical research.
-
AION Labs Launches CombinAble.AI To Reduce Time And Cost Of Targeted Antibody Design, Advancing Optimization Of Drug Development
3/12/2024
AION Labs, the first-of-its-kind venture studio spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the launch of CombinAble.AI.
-
GV20 Therapeutics Joins NVIDIA Inception To Develop AI Models For Drug And Target Discovery
3/12/2024
GV20 Therapeutics, a clinical stage biotechnology company integrating AI, genomics, and disease biology to create next-generation antibody therapeutics for cancer, announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.
-
AbCellera To Collaborate With Biogen To Discover Therapeutic Antibodies For Neurological Conditions
3/11/2024
AbCellera and Biogen Inc. have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience.
-
Ubiquigent Enters Agreement With Astellas Subsidiary, Nanna Therapeutics
3/11/2024
Ubiquigent Limited (Ubiquigent), a drug discovery and development company harnessing novel deubiquitinase (DUB) modulators as new therapeutics for areas of high unmet medical need, today announced an agreement with Nanna Therapeutics (Nanna).
-
Everest Medicines Announces Acceptance Of VELSIPITY® New Drug Application In Macau
3/10/2024
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced the Pharmaceutical Administration Bureau of the Macau Special Administrative Region, China, has accepted Everest's New Drug Application (NDA) for VELSIPITY® (etrasimod) for the treatment of adult patients with moderately to severely active ulcerative colitis.
-
ICR Scientists Seek New Drugs To Treat Childhood Cancer As Part Of Global Cancer Grand Challenges Team
3/6/2024
A global, interdisciplinary team of researchers has been selected to receive a Cancer Grand Challenges award of up to $25m over five years to tackle the challenge of solid tumours in children.
-
Verastem Oncology Receives Orphan Drug Designation From FDA For Avutometinib Alone Or In Combination With Defactinib In Recurrent Low-Grade Serous Ovarian Cancer
3/5/2024
Verastem Oncology a biopharmaceutical company committed to advancing new medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to avutometinib, a RAF/MEK clamp, alone or in combination with defactinib, a selective FAK inhibitor, for the treatment of all patients with recurrent low-grade serous ovarian cancer (LGSOC).
-
Elsevier And Iktos Partner To Deliver An AI-Driven Synthetic Chemistry Platform For Drug Discovery
3/5/2024
Elsevier, a global leader in information and data analytics, has signed a multi-year agreement with Iktos(opens in new tab/window), a company specializing in artificial intelligence for new drug discovery.
-
NovAliX And Max Planck Join Forces To Advance Cryo-EM Driven Drug Discovery
3/5/2024
NovAliX, a specialized Contract Research Organization dedicated to enabling drug discovery, today announces its long-term strategic partnership with the Max Planck Institute (MPI) for Multidisciplinary Sciences in Göttingen.